Global Health Q2 FY27 Earnings Call: Rs. 6,000 Cr Capex To Double Capacity, Noida Breaks Even Within A Year (MEDANTA)

Global Health Ltd held its Q2 FY27 earnings call on November 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Volume-led quarter with sharp margin expansion

• Revenue from operations of Rs.14,690 million (+34% YoY) — Q2 FY 2026-2027 consolidated; note that Medanta has moved to reporting "revenue from operations" (excludes other income, primarily interest income) and "operating EBITDA" (excludes other income, after ESOP expenses), with comparatives restated like-for-like.
• Operating EBITDA of Rs.3,701 million (+60% YoY) at a 25.2% margin vs 21% in Q2 FY 2025-2026; PAT of Rs.2,191 million vs Rs.1,584 million (+38% YoY).
• Inpatient volumes +30% YoY, outpatient +38% YoY, occupied bed days +22% in Q2 FY 2026-2027; network occupancy 67% vs 64% in Q2 FY 2025-2026.
• ARPP +3% YoY to Rs.2.06 lakhs on favorable case mix and high-acuity contribution; ALOS improved to 2.89 days from 3.06 days.
• International patient revenue +30% YoY to Rs.993 million; OPD pharmacy revenue +53% YoY to Rs.699 million (hospital plus retail pharmacy network).
• Net cash surplus of Rs.7,815 million as of September 30, 2026 vs Rs.5,906 million as of March 31, 2026; H1 FY 2026-2027 operating cash flow of Rs.5,678 million.

Noida break-even anchors Cluster 2 outperformance

• Medanta Noida (550 beds) achieved EBITDA break-even in Q2 FY 2026-2027, within a year of its November 2025 inauguration — revenue from operations Rs.1,059 million, operating EBITDA Rs.86 million vs an EBITDA loss of Rs.199 million in Q2 FY 2025-2026; 49 beds added, operational capacity now 482 beds.
• Cluster 2 (Lucknow, Patna, Noida) revenue of Rs.5,790 million (+63% YoY) with operating EBITDA of Rs.1,837 million (+110% YoY), aided by Noida break-even; IP volumes +52%, ARPP +8%, occupancy 67% vs 62%.
• Cluster 2 IP growth ex-Noida at ~26% in Q2 FY 2026-2027 — management said there was no significant shift in payer mix; growth follows the volume-led philosophy via clinical talent additions and strength in Lucknow and Patna.
• Cluster 1 (Gurugram, Indore, Ranchi) revenue of Rs.8,229 million (+18% YoY), operating EBITDA Rs.1,810 million (+29% YoY) at 22% margin; IP volumes +15%, ARPP +2%, occupancy 66% vs 61%.
• Cluster 2 occupancy above Cluster 1 in Q2 FY 2026-2027 — management attributed this to Gurgaon's 1,500-bed facility with 42 operating rooms and 7-8 cath labs driving high procedural volumes with faster throughput, while Cluster 2 units see more medical-management cases (longer stays, lower realizations), partly due to a shortage of high-quality ICU care in those regions.
• Management operates in the 65-67% occupancy range, which it says delivers healthy fixed-cost recovery, and cautioned against judging occupancy in isolation — advising triangulation with realizations, ARPP/ARPOB, length of stay and volumes.
• Cluster 1 margin dispute: an analyst cited a 210 bps sequential margin decline to ~22% in Q2 FY 2026-2027 from ~24% in Q1 FY 2026-2027; management disputed the figures, stating Cluster 1 margins expanded and directing the analyst to the company presentation — no driver was confirmed.

Ghaziabad land win; ~3,450 beds and Rs.6,000 Cr capex ahead

• Ghaziabad land parcel of ~2.6 acres allotted at Rs.166 crores via online e-auction (freehold, Siddharth Vihar Yojana) in Q2 FY 2026-2027; board approved a 500-bed multi-specialty hospital with total capex of ~Rs.1,000 crores (spend period unspecified), targeting the Ghaziabad/Western UP catchment (Eastern Delhi, Meerut, Saharanpur, Hapur, Bulandshahr).
• ~3,450 beds expected to be added over the next few years, nearly doubling network capacity to over 7,600 beds; planned capex of over Rs.6,000 crores over the next 4-5 years covering upcoming hospitals, existing-facility expansion and supporting infrastructure.
• South Delhi (GK), Mumbai and Guwahati greenfields expected to be completed and operations started around FY30, per management's response on the pipeline coming after FY27.
• Project-level status: South Delhi (GK) construction is progressing well but may see slowdown/stoppage over the next one or two months (Q3 FY 2026-2027) due to pollution-linked construction norms; Guwahati has all approvals with work restarted after the monsoon; Mumbai has most approvals with digging set to begin; Varanasi drawings submitted awaiting approvals; Ghaziabad approval applications yet to be filed.
• Pitampura is the only delayed project versus the Q1 FY 2026-2027 update, pending revised drawings and revised approvals.
• 74 beds added in Q2 FY 2026-2027 (49 Noida, 25 Lucknow) to 3,811 operational beds; over the next couple of quarters Medanta will add 6 OTs + 2 cath labs at Gurugram, 4 OTs + 1 cath lab at Patna, and 5 OTs at Lucknow.
• Lucknow expansion: capacity at almost 800 beds vs 950 capacity; some bed additions planned during Q3 FY 2026-2027; ~5 operating rooms hoped to come on board in Q3 FY 2026-2027 or possibly early Q4 FY 2026-2027; a new OPD floor in the coming months of FY 2026-2027 to add ~20-30% to outpatient capacity.

Cluster 2 margin jump explained; no margin guidance given

• Cluster 2 ex-Noida (Lucknow + Patna) EBITDA margin rose ~640 bps to ~37% in Q2 FY 2026-2027 — management confirmed there were no one-off or exceptional items in either the current or prior-year period, ruling out insurance reversals / government scheme settlements raised by the analyst.
• Corporate cost allocation flatters Cluster 2: all corporate costs and overheads are loaded on the Gurgaon unit (Cluster 1); Cluster 2 carries no corporate cost loading, so its margins are structurally higher to that extent.
• Operating leverage from modest bed additions: Lucknow and Patna are reasonably mature (~5-6 years old); even 30-50 bed additions provide leverage as hospitals scale; Cluster 2 occupied bed days rose ~40% (including Noida) and volumes grew ~20% ex-Noida in Q2 FY 2026-2027.
• No margin guidance: management declined to guide on Q3/Q4 FY 2026-2027 margins; Pankaj Sahni noted quarterly results reflect efforts over 18-24 months and prioritizes long-term sustainability over quarter-to-quarter margins.
• Q3 FY 2026-2027 flagged as normally a softer quarter due to the festival season (per CFO Yogesh Kumar Gupta); management is willing to add costs of hiring more doctors to drive growth in future quarters — quarter-to-quarter variations possible, but no structural shift expected.
• Results lag actions by 12-18 months: management said Q2 FY 2026-2027 performance was supported by capacity additions made over the previous three quarters, with nothing done specially for the quarter.

Volume-over-tariff stance intact; oncology drug cap impact "too early"

• ARPP approach unchanged: management reiterated growth is driven through volume rather than tariff; Patna had zero tariff increases for ~4-5 years and Lucknow for ~3-4 years, and revisions when applied are nominal at 5% or less.
• On FY28 ARPP trajectory (analyst premise: institutional utilization optimal and bed additions largely complete in FY27), management said growth will keep coming from complex work and newly added specialties (e.g., BMT, liver transplant) and expects "some tariff-related changes over coming years and coming quarters" but does not expect to fundamentally change its ARP approach.
• Oncology drug margin cap impact too early to evaluate — management said the matter is still evolving, with issues pending at the court, government and industry levels, and the impact for ongoing/upcoming quarters cannot yet be assessed.
• Management framed the regulation as aligned with Medanta's access-expansion philosophy, citing early large-scale entries into Lucknow and Patna and support for schemes like Ayushman at the Gurgaon facility; over a 3-4 year horizon, capacity/access expansion has historically helped financial returns as operating leverage kicks in.
• Management cited the 2016 cardiac implant price regulation as precedent, noting that after 10 years the hospital industry and med tech players have seen mass benefits in access and affordability; the CFO added that in cardiology, after prices were capped, volumes and access increased over the longer run.
• Oncology price cuts will not impact Medanta's investment plans (per CFO), as investments will be earned by demand that already exists; management pushed back on the premise that oncology is the highest-margin specialty, noting drug prices affect medical oncology realization while surgical and radiation oncology also carry profitability.
• CGHS/institutional mix: the CFO affirmed Medanta will continue serving all communities — Ayushman Bharat, CGHS, ECHS — including at Gurgaon; he tentatively attributed the analyst's observation that CGHS share has stagnated at ~10-11% to Noida, which currently has no CGHS-linked volume.

Retail pharmacy doubling since FY25; disclosure changes ahead

• Retail pharmacy outlets expanded from 8 to 17 since FY25 (per analyst Sandhya, Unicorn Asset Management); management framed pharmacy, retail labs and home care as adjacencies providing continuity of care around Medanta's hospitals and clinics under a hub-and-spoke philosophy.
• "Huge amount of headroom" seen in retail adjacencies because the market is vastly unorganized and in many cases not of the highest quality standards, though the company will take measured steps; expansion is done in sync with hospital builds, in some cases preemptively (e.g., building Northeast presence ahead of the Guwahati hospital opening).
• Surgical vs non-surgical revenue split may be disclosed from Q3 FY 2026-2027 — management declined to quantify it now ("don't want to give a wrong number"); the CFO to review and potentially include the split in the Q3 FY 2026-2027 presentation; no significant structural gap seen across hospitals.
• Hospital-wise ARPOB/ARPP disclosure to remain cluster-level only — management declined to share Lucknow/Patna/Noida separately; no significant ARPOB shifts in Q2 FY 2026-2027, only ~1-2% changes mainly from rate and case-mix.
• Drugs & consumables contribution not disclosed — the company tracks revenue at the specialty level only; drugs/consumables flow into packages and departmental consumption, making the split impracticable.
• Package-based billing within IPD covers most cardiac and orthopedic work, part of obs & gynae, and government-mandated schemes (CGHS, etc.), with few packages beyond these per the Group CEO.
• Upcoming hospitals to follow the full-scale Lucknow/Patna/Noida launch philosophy — one-shot construction enables better clinical flows and infection management; robotic surgery and radiation oncology equipment are now standard opening purchases; some tier-2 towns may see slower talent hiring/ramp-up (no timeline specified).